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Contribution of progenitor cells sharing some serotonergic proteins in
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Many compounds (pergolide, fenfluramine, ectasy) were described as
inducers of fibrotic valvular lesions. All these compounds share in common to
activate the 5HT2B serotonergic receptor. This observation leads to the
hypothesis that cardiac valves express a « serotonergic system » that could be
activated by serotonin (5-HT) or 5-HT receptor (5-HTR) agonists. In this
work, we characterized the expression pattern of 5-HT2A, 2B, 4 R and the 5-
HT transporter (SERT) in whole and cell subpopulations of 30 human mitral
and aortic valves collected at the time of surgical valve replacement (Aortic:
11 calcified, 5 sclerotic, 4 bicuspid; Mitral: 12 dystrophic). All samples
express 5HT2A, 2B, 4 R and SERT, the amount of 5HT2B R mRNA being
higher than the 5HT2A R whatever the valve and etiology. 5HT2BR expres-
sion is found in endothelial cells (CD31+) at the valve surface, but also inside
valve lesions, expressed by interstitial cells (smooth muscle α-actin and
vimentin positive cells) located in an abundant glycosaminoglycan matrix. In
fact, fibromyxoid lesions and calcified aortic valves express a high amount of
CD34+ cells. These cells are endothelial progenitors because they express
VEGFR2 and eNOS together with 5-HT2R. After collagenase treatment, valve
samples were labeled with CD31 and CD34 antibodies: 60.1 (± 11) % of all
mitral valvular cells are CD34+ compared to 36.1 (±8) % of aortic valvular
cells (FACS analysis and sorting). To summarize, 5HT2A, 2B, 4 receptors and
SERT are expressed in aortic and mitral diseased valves. The amounts of
5HT2A, 2B R mRNA are equivalent between mitral and aortic valves. High
amount of CD34+ endothelial progenitors, expressing 5HT2AR and 5HT2BR,
are found in degenerated valves. The contribution of the two 5-HT2 receptors
and endothelial progenitors in valve degeneration is now under investigation.
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Nonsyndromic mitral valve prolapse (MVP) is a common degenerative val-
vulopathy of unknown aetiology that predisposes to heart failure and sudden
death. Here we investigate functional evidence for candidate genes near
genome-wide association study (GWAS) loci to understand the mechanisms
underlying the genetic susceptibility to MVP. To prioritize genes, we used
literature and databases (e. g ENCODE, eQTLs). We analysed the expression
pattern of 3 candidate genes during valve development in mouse embryos by
immunohistochemistry (IHC) i) completion of endothelial-to-mesenchymal
transformation (E13.5), ii) valve sculpting and elongation (E17.5) and iii)
adult form (9 months). Morpholino knockdown (KD) was performed for
8 genes in zebrafish and assayed the function of developing atrioventrocular
(AV) canal by scoring the embryos according to the presence of erythrocyte
regurgitation. On chr3, the association is in an intron of LMCD1, a repressor
of GATA6 previously implicated in cardiac hypertrophy. KD of Lmcd1 in
zebrafish resulted in a significant atrioventricular valve defect with regurgita-
tion. On Chr2, the associated variants were upstream to TNS1 encoding a focal
adhesion and actin-interacting protein. Tensin1 is expressed during valve mor-
phogenesis in mice and maintained in the adult endothelial and valvular inter-
stitial cells. Hematoxylin and eosin histological staining in 9-month Tns1-/-
mice show enlarged posterior mitral leaflets with myxomatous aspects. In
addition, zebrafish KD of Tns1 induced AV regurgitation. The functional
validation of genes located in or near MVP susceptibility loci identifies new
MVP mechanisms and stresses the role of cytoskeleton integrity in valve
development. This study reveals LMCD1 and TNS1 at play as early as during
valve development and can potentially be targeted during adulthood to
improve the natural history of MVP.
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Heart valves diseases affect 3% of world population, and surgery is often
the only therapeutic mean. A genetic study performed on a family in which
several members exhibited a MVP identified a R94G mutation on LRRFip1
gene. LRRFip1 alternative transcription splicing gives rise to five isoforms in
humans, three of which are targeted by the mutation (Iso1, 3 and 4). Previous
studies only focused on LRRFip1-iso5 that was first described as a transcrip-
tion factor interacting with positive (Dishevelled) and negative (Flightless-1)
regulators of the canonical Wnt β-catenin dependant pathway. As it may par-
ticipate and regulate crucial events of cardiac valve development and homeo-
stasis involving Wnt pathway, we hypothesised that LRRFip1 could be
involved in MVP pathology. We first analysed the expression of LRRFip1 in
valves by RNA sequencing and quantitative PCR and showed that LRRFip1-
iso1 is expressed in human valves. In mouse, it prevails during embryonic
development and then levels down to that other isoforms expression. We thus
focused on LRRFip-iso1. Using cell fractionation, we showed a nuclear loca-
lization of LRRFip1-iso1 while other isoforms are strictly cytoplasmic. Using
luciferase-based Wnt reporter assays and co-IP, we further demonstrated that
out of the five isoforms, LRRFip1-iso1 is the strongest interactor of Dvl-1 and
Fli-1, and the strongest activator of the canonical Wnt pathway. Although acti-
vation requires beta-catenin, it does not involve beta-catenin stabilization nor
activation. Using site directed mutagenesis, we mapped the domain respon-
sible for Wnt pathway activation to the 25 amino-acids region surrounding
arginine 94 and showed that R94G mutation also decreases Wnt activation.
This work demonstrates the involvement of LRRFip1-iso1 in canonical Wnt
pathway activation. Taken together, our results suggest a potential role for
LRRFip1 in valvulogenesis and/or valve homeostasis regulation that may be
impeded by the R94G mutation.
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